---
title: "Sanofi Consumer Healthcare India Ltd (SANOFICONR) — Share Price, Financials & Analysis"
symbol: "SANOFICONR"
company: "Sanofi Consumer Healthcare India Ltd"
canonical: "https://tapetide.com/stocks/SANOFICONR"
isin: "INE0UOS01011"
nse_symbol: "SANOFICONR"
bse_code: "544250"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 9378.07
generated_at: "2026-09-13T19:03:42.526Z"
---

# Sanofi Consumer Healthcare India Ltd (SANOFICONR)

Canonical page: https://tapetide.com/stocks/SANOFICONR

## Company

- **NSE Symbol:** SANOFICONR
- **BSE Code:** 544250
- **ISIN:** INE0UOS01011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-09-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** sanofi.in

## About

Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]

## Latest Price

- **Price:** ₹4023.4
- **Change:** -66.2 (-1.62%)
- **Open:** ₹4099
- **Day High:** ₹4113.5
- **Day Low:** ₹4001.1
- **Previous Close:** ₹4089.6
- **Volume:** 4396
- **As Of:** 2026-09-11T09:59:47+00:00

## Key Fundamentals

Observed at 2026-09-11T04:43:41.050704Z.

- **Market Cap:** ₹9378.07 Cr
- **Classification:** Microcap
- **P/E (reported):** 35.6
- **P/E (TTM):** 34.84
- **EPS (TTM):** ₹115.49
- **Book Value:** ₹151.07
- **Price to Book:** 27.2
- **Dividend Yield:** 1.83%
- **ROE:** 62.53%
- **ROCE:** 76.99%
- **Debt to Equity:** 0.06
- **Revenue (yearly):** ₹896.8 Cr
- **Net Income:** ₹240.1 Cr
- **EBITDA:** ₹327.4 Cr
- **52-Week High:** ₹5357
- **52-Week Low:** ₹3975
- **RSI (14):** 32.24

## Tapetide Score

- **Score:** 57 / 100
- **Score date:** 2026-09-04
- **Archetype:** Losing Momentum
- **What it means:** A capable business whose price trend has turned while the multiple is still demanding. Often a re-rating in progress rather than a broken company — watch whether earnings stay resilient.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Falling
- **Percentile:** 77.8 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 81.57 | 9% |
| growth | 81.26 | 9% |
| momentum | 26.56 | 12% |
| ownership | 52.67 | 24% |
| quality | 71.42 | 22% |
| valuation | 47.27 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 77.6%
- Company has been maintaining a healthy dividend payout of 49.3%

### Weaknesses

- Stock is trading at 26.6 times its book value

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| cash flow growth | — | -60.18% | — |
| ebitda margin growth | 1.27% | -5.05% | -8.36% |
| net income growth | 1.47% | 32.65% | 45.6% |
| revenue growth | 3.07% | 21.6% | 17.03% |
| roce | — | -7.65% | -24.34% |
| roe | — | -5.69% | 69.42% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 |
| OPM % | 45 | 40 | 37 | 37 | 39 | 36 | 37 | 32 | 36 | 36 | 39 | 38 |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 |
| Tax % | 25 | 24 | 25 | 25 | 26 | 29 | 25 | 23 | 25 | 27 | 25 | 25 |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 |
| EPS in Rs | — | — | — | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 8m | Dec 2024 | Mar 2025 | Dec 2025 | TTM |
| --- | --- | --- | --- | --- | --- |
| Sales | 555 | 724 | 878 | 878 | 950 |
| Expenses | 337 | 454 | 569 | 569 | 597 |
| Operating Profit | 219 | 271 | 309 | 309 | 353 |
| OPM % | 39 | 37 | 35 | 35 | 37 |
| Other Income | 2 | -15 | 25 | 25 | 20 |
| Interest | 0 | 4 | 2 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 | 13 |
| Profit before tax | 219 | 247 | 320 | 320 | 357 |
| Tax % | 25 | 27 | 25 | 25 | — |
| Net Profit | 165 | 181 | 240 | 240 | 266 |
| EPS in Rs | — | 78.59 | 104.25 | 104.25 | 115.49 |
| Dividend Payout % | 6 | 70 | 0 | 72 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Dec 2024 | Dec 2025 | Jun 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 2 | 23 | 23 | 23 |
| Reserves | 206 | 250 | 361 | 325 |
| Borrowings | 0 | 20 | 25 | 21 |
| Other Liabilities | 138 | 138 | 138 | 338 |
| Total Liabilities | 345 | 431 | 547 | 706 |
| Fixed Assets | 5 | 29 | 36 | 30 |
| CWIP | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 338 | 402 | 511 | 677 |
| Total Assets | 345 | 431 | 547 | 706 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 439 | — | 175 |
| Cash from Investing Activity | 0 | 2 | — | 8 |
| Cash from Financing Activity | 2 | -116 | — | -134 |
| Net Cash Flow | 2 | 325 | — | 48 |
| Free Cash Flow | -4 | 429 | — | 167 |
| CFO/OP | 2 | 208 | — | 85 |

### Ratios

| Item | Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Debtor Days | 21 | 7 | — | 12 |
| Inventory Days | 232 | 80 | — | 98 |
| Days Payable | 144 | 138 | — | 126 |
| Cash Conversion Cycle | 109 | -51 | — | -16 |
| Working Capital Days | 134 | -33 | — | -4 |
| ROCE % | — | 111 | — | 90 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% |
| FIIs | 6.03% | 5.22% | 4.42% | 4.53% | 3.24% | 2.94% | 2.83% | 2.76% | 2.6% |
| DIIs | 20.87% | 24.03% | 25.35% | 25.48% | 16.89% | 17.21% | 17.33% | 17.57% | 17.86% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 7.71% | 7.53% | 7.01% | 6.58% | 6.3% | 6.26% | 6.25% | 6.26% | 6.18% |
| Others | 5% | 2.83% | 2.83% | 3.01% | 2.3% | 2.32% | 2.31% | 2.14% | 2.1% |
| No. of Shareholders | 61091 | 61091 | 55734 | 51859 | 49632 | 48808 | 48075 | 48418 | 47511 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 4 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 4121.16 | Sell |
| EMA (10) | 4114.69 | Sell |
| SMA (20) | 4174.39 | Sell |
| EMA (20) | 4192.3 | Sell |
| SMA (50) | 4412.79 | Sell |
| EMA (50) | 4352.44 | Sell |
| SMA (100) | 4554.09 | Sell |
| EMA (100) | 4449.42 | Sell |
| SMA (200) | 4475.31 | Sell |
| EMA (200) | 4535.22 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 28.28 | Buy |
| MACD (12,26,9) | -104.22 | Sell |
| Stochastic (14,3,3) | 12.31 | Buy |
| ADX (14) | 14.63 | Neutral |
| Williams %R (14) | -92.58 | Buy |
| ATR (14) | 105.55 | Neutral |
| ROC (12) | -3.25 | Sell |
| Stoch RSI (14) | 45.56 | Neutral |
| UO (7,14,28) | 39.32 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:43:41.048289+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2768754-06ef-45d6-b16d-8df23af2ef40.pdf) |
| 2026-07-28 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday 28Th July 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a32239ba-2656-4783-838e-ba424af7f7a3.pdf) |
| 2026-07-28 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc035775-5bf1-49f3-a4c0-deb6adfc8878.pdf) |
| 2026-07-22 | [Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1166c346-4b21-4378-98d4-a12da0db2c0d.pdf) |
| 2026-07-09 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4fbbf544-1751-44e4-a335-61a7156c1887.pdf) |
| 2026-06-29 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4646fce-e10e-42a2-95ed-6958c44e24bb.pdf) |
| 2026-06-29 | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4367128-3f9a-4c05-805d-00bd0f0c5b36.pdf) |
| 2026-06-26 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c208e1d-ec55-47dc-ab62-5e3f1d3d8cea.pdf) |
| 2026-06-26 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c199be6-c35c-4473-831f-03a2da9ad83c.pdf) |
| 2026-06-05 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fab237f9-a769-47e9-8838-16c85586d262.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-28 | [Results - Financial Results For June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67c72ee0-e4aa-4dc3-abad-60ae16f5fd6a.pdf) |
| 2026-04-28 | [Results - Financial Results For March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a209d473-7fc4-4b1d-a804-392efff2c333.pdf) |
| 2026-02-25 | [Outcome Of Board Meeting For Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ebfde72-b1e6-4a1b-b0ea-2ab24cdacb0e.pdf) |
| 2025-11-12 | [Results-Financial Results For September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a46e9253-52ff-45f2-b11a-0bbbb810e2ce.pdf) |
| 2025-08-04 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Monday 4Th August 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1d83fa0-2234-4c75-8616-cf88c32dcf1b.pdf) |
| 2025-08-04 | [Outcome Of Board Meeting Held On Monday 4Th August 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11b67b15-ac27-44af-91e8-dec9da861d90.pdf) |
| 2025-05-02 | [Board Meeting Outcome For Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5bcab2a-309a-499b-9726-09f6ae550ea7.pdf) |
| 2025-02-20 | [Approved The Audited Standalone Financial Statements Of The Company For The Quarter And Financial Year Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fbf8bf2b-82a2-4728-b900-eb1d44a4f69e.pdf) |
| 2024-11-12 | [Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8c2d896-d38b-439e-95e1-4adaa499ecc1.pdf) |
| 2024-09-13 | [Results-Financial Results For Quarter And Half Year Ended June 30 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad4c069e-736f-48e5-a81b-c81dbbc349b5.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Board meeting on 28 April 2026 to approve Q4 FY26 unaudited results; trading window closed till 30 April. | [Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 31St March 2026 9h - Board meeting on 28 April 2026 to approve Q4 FY26 unaudited results; trading window closed till 30 April.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/9b08bfea-fe9b-4459-9872-8034c4b46fe7.pdf) |
| 9 Apr - Regulation 74(5) certificate for quarter ended 31 March 2026 submitted. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Regulation 74(5) certificate for quarter ended 31 March 2026 submitted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/871e72ba-6231-421b-92d8-e1c2d54e508a.pdf) |
| 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d6849380-d2d8-4739-b881-218356304b4f.pdf) |
| 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d6849380-d2d8-4739-b881-218356304b4f.pdf) |
| 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute. | [Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1a0dc9c-5cec-4ba5-8174-3d3a5f56b073.pdf) |
| 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute. | [Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f1a0dc9c-5cec-4ba5-8174-3d3a5f56b073.pdf) |
| 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1c0e574-9cef-442b-bcd9-b362f0f020d8.pdf) |
| 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f1c0e574-9cef-442b-bcd9-b362f0f020d8.pdf) |
| 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million. | [Results - Financial Results For March 31, 2026 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a209d473-7fc4-4b1d-a804-392efff2c333.pdf) |
| 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million. | [Results - Financial Results For March 31, 2026 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a209d473-7fc4-4b1d-a804-392efff2c333.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-03-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c1503a1-2b27-40f5-b4d4-6f066c0072d1.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-03-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91e302d2-942e-492d-a169-0dc3507854ff.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Mar 2026 | [Concall - Mar 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/91e302d2-942e-492d-a169-0dc3507854ff.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d61275c9-1a2c-49c4-8f5a-347797531cde.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2a28961f-a768-4d2b-bc3f-836b2cd1e545.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:03:42.526Z.